Overview

Efficacy and Safety Trial of 12 Weeks of Treatment With Nebulized SUN-101 in Patients With COPD

Status:
Completed
Trial end date:
2015-11-01
Target enrollment:
Participant gender:
Summary
This is a trial of 12 weeks of treatment with nebulized SUN-101 using an Investigational eFlow® Closed System (CS) nebulizer in subjects with chronic obstructive pulmonary disease (COPD) according to the Global Initiative for Chronic Obstructive Lung Disease (GOLD 2014) guidelines.
Phase:
Phase 3
Details
Lead Sponsor:
Sunovion Respiratory Development Inc.